Health Catalyst (HCAT) Expected to Announce Earnings on Thursday

Posted by Geri Gentry on Jul 30th, 2026

Health Catalyst (NASDAQ:HCAT – Get Free Report) is projected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $0.02 per share and revenue of $69.0030 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Health Catalyst (NASDAQ:HCAT – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of $0.01 by $0.01. The company had revenue of $70.76 million during the quarter, compared to analyst estimates of $69.24 million. Health Catalyst had a negative return on equity of 3.52% and a negative net margin of 87.69%. On average, analysts expect Health Catalyst to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Health Catalyst Stock Up 0.9%

Health Catalyst stock opened at $2.16 on Thursday. The stock has a market cap of $159.60 million, a PE ratio of -0.58 and a beta of 1.56. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.69 and a current ratio of 1.69. Health Catalyst has a one year low of $0.96 and a one year high of $3.95. The stock has a fifty day moving average of $1.86 and a 200 day moving average of $1.71.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on HCAT shares. Canaccord Genuity Group boosted their price target on Health Catalyst from $2.00 to $3.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Cantor Fitzgerald reissued a “neutral” rating on shares of Health Catalyst in a report on Monday, May 11th. Citigroup restated a “neutral” rating on shares of Health Catalyst in a research report on Thursday, July 23rd. Weiss Ratings upgraded shares of Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Finally, Stephens decreased their price target on shares of Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Health Catalyst currently has a consensus rating of “Hold” and an average price target of $2.93.

Read Our Latest Research Report on Health Catalyst

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. AQR Capital Management LLC grew its stake in shares of Health Catalyst by 816.8% during the 1st quarter. AQR Capital Management LLC now owns 168,344 shares of the company’s stock valued at $763,000 after acquiring an additional 149,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock worth $163,000 after acquiring an additional 2,624 shares during the period. Focus Partners Wealth bought a new stake in Health Catalyst during the 1st quarter worth approximately $46,000. Geode Capital Management LLC lifted its holdings in Health Catalyst by 11.4% during the second quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock valued at $6,269,000 after purchasing an additional 169,580 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Health Catalyst by 13.5% in the second quarter. Rhumbline Advisers now owns 101,986 shares of the company’s stock worth $384,000 after purchasing an additional 12,127 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

(Get Free Report)

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.